Search research articles
Contact Us
Filters
Showing results (11-20 of 79) with videos related to
Page
of 8
Sort By:
Expert Review of Anticancer Therapy
|
December 21, 2004
Endocrine therapy and other targeted therapies for metastatic breast cancer
Syed A Hussain, Daniel H Palmer, Sarah Moon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 14, 2007
Molecularly targeted therapeutics for breast cancer
Syed A Hussain, Daniel H Palmer, David Spooner, et al.
Molecular Cancer
|
March 10, 2010
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus
Taha Elmetwali, Peter F Searle, Iain McNeish, et al.
Nature Reviews. Gastroenterology & Hepatology
|
May 3, 2018
Therapeutic developments in pancreatic cancer: current and future perspectives
John P Neoptolemos, Jörg Kleeff, Patrick Michl, et al.
Expert Review of Anticancer Therapy
|
October 18, 2008
Biology of testicular germ cell tumors
Syed A Hussain, Yuk Ting Ma, Daniel H Palmer, et al.
Scientific Reports
|
January 17, 2020
CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
Taha Elmetwali, Asmaa Salman, Wenbin Wei, et al.
Future Oncology (London, England)
|
December 5, 2019
Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study
Daniel H Palmer, Neil S Hawkins, Valérie Vilgrain, et al.
British Journal of Cancer
|
January 13, 2017
Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre
Olusola O Faluyi, Joanna L Connor, Madhuchanda Chatterjee, et al.
Expert Review of Anticancer Therapy
|
December 13, 2005
Role of chemotherapy in breast cancer
Syed A Hussain, Daniel H Palmer, Andrea Stevens, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 10, 2017
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Tim Meyer, Daniel H Palmer, Ann-Lii Cheng, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 79) with videos related to
Sort By:
Page
of 8
Expert Review of Anticancer Therapy
|
December 21, 2004
Endocrine therapy and other targeted therapies for metastatic breast cancer
Syed A Hussain, Daniel H Palmer, Sarah Moon, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 14, 2007
Molecularly targeted therapeutics for breast cancer
Syed A Hussain, Daniel H Palmer, David Spooner, et al.
Molecular Cancer
|
March 10, 2010
CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus
Taha Elmetwali, Peter F Searle, Iain McNeish, et al.
Nature Reviews. Gastroenterology & Hepatology
|
May 3, 2018
Therapeutic developments in pancreatic cancer: current and future perspectives
John P Neoptolemos, Jörg Kleeff, Patrick Michl, et al.
Expert Review of Anticancer Therapy
|
October 18, 2008
Biology of testicular germ cell tumors
Syed A Hussain, Yuk Ting Ma, Daniel H Palmer, et al.
Scientific Reports
|
January 17, 2020
CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
Taha Elmetwali, Asmaa Salman, Wenbin Wei, et al.
Future Oncology (London, England)
|
December 5, 2019
Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study
Daniel H Palmer, Neil S Hawkins, Valérie Vilgrain, et al.
British Journal of Cancer
|
January 13, 2017
Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre
Olusola O Faluyi, Joanna L Connor, Madhuchanda Chatterjee, et al.
Expert Review of Anticancer Therapy
|
December 13, 2005
Role of chemotherapy in breast cancer
Syed A Hussain, Daniel H Palmer, Andrea Stevens, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 10, 2017
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Tim Meyer, Daniel H Palmer, Ann-Lii Cheng, et al.
Page
of 8